BROWSE·page 366 of 1443

Browse EX-10 agreements

17,311 total material contract exhibits.


EX-10.1

Nordicus Partners Corp

EX-10.1·8-K·CIK 1011060·ACC 0001493152-26-041470·Filed Sep 04, 2026, 09:15 ET

EX-10.1

OXFORD INDUSTRIES INC

OXFORD INDUSTRIES, INC.

AMENDED AND RESTATED

LONG-TERM STOCK INCENTIVE PLAN

(as of June 23, 2026)

1.Purpose. The purpose of the Oxford Industries, Inc. Amended and Restated Long-Term Stock Incentive Plan (the “Plan”) is to attract and retain employees and directors for Oxford Industries, Inc. and its subsidiaries and to provide such persons with incentives and rewards for superior performance.

2.Definitions. The following terms shall be defined as set forth below:

(a)“Award” means any Option, Stock Appreciation Right, Restricted Share, Restricted Share Unit, or Other Stock-Based Award.

(b)“Board” means the Board of Directors of the Company.

(c)“Code” means the Internal Revenue Code of 1986, as amended from time to time.

(d)“Committee” means a committee of the Board charged with administering the Plan as described in Section 4.

(e)“Company” means Oxford Industries, Inc., a Georgia corporation, or any successor corporation.

(f)“Director” means a member of the Board.

(g)“Employee” means any person, including an officer, employed by the Company or a Subsidiary.

…

EX-10.1·10-Q·CIK 75288·ACC 0000075288-26-000084·Filed Sep 04, 2026, 08:46 ET

EX-10.1

Blue Owl Technology Finance Corp.

**EXECUTION VERSION **

Blue Owl Technology Finance Corp.

$150,000,000 7.60% Series 2026A Senior Notes, due September 3, 2032

Master Note Purchase Agreement

Dated September 3, 2026


**TABLE OF CONTENTS **

| | | | | | | | | -------------------------------------------------------- | - | -------------------------------------------------------------------- | : | :------: | : | - | | | | | | | | | | | | | | Page | | | | SECTION 1. AUTHORIZATION OF NOTES | | | | | 1 | |

…

EX-10.1·8-K·CIK 1747777·ACC 0001193125-26-382839·Filed Sep 04, 2026, 08:30 ET

EX-10.2

Bandwidth Inc.

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of September 1, 2026, by and between Bandwidth Inc.("Bandwidth"), a Delaware corporation with its principal place of business at 2230 Bandmate Way, Raleigh, North Carolina 27607, and Emily Harlan ("Executive").

BACKGROUND

A.     Executive was promoted to Bandwidth’s General Counsel and Secretary effective September 1, 2026.

B.    Bandwidth and Executive now desire to enter into this Agreement in order to formalize the terms and conditions of Executive’s employment pursuant to this Agreement.

C.    All initially capitalized terms are either defined herein (but not necessarily where first used) or are defined in Exhibit Aattached hereto and incorporated herein by this reference.

AGREEMENT

In consideration of the foregoing, the agreements made herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

…

EX-10.2·8-K·CIK 1514416·ACC 0001514416-26-000064·Filed Sep 04, 2026, 08:14 ET

EX-10.1

Bandwidth Inc.

August 31, 2026

Mr. R. Brandon Asbill

c/o Bandwidth Inc.

Dear Brandon,

On behalf of the Board of Directors and the leadership team at Bandwidth Inc., in connection with your retirement I want to express my gratitude for your contributions as our General Counsel. Your tenure has been marked by exceptional judgment, unwavering integrity, and a commitment to this company that has made a lasting difference.

This letter confirms the terms we have discussed regarding your transition. Effective September 1, 2026 and continuing through December 31, 2026 (the “Termination Date”), you will assume the role of General Counsel Emeritus and Assistant Secretary, reporting to the incoming General Counsel Emily Harlan in that capacity.  In exchange for your service as General Counsel Emeritus and Secretary, you will continue to receive base salary at your current rate through the Termination Date.  We are grateful that you have agreed to remain available to the company in this advisory role, and we look forward to continuing to benefit from your counsel.

…

EX-10.1·8-K·CIK 1514416·ACC 0001514416-26-000064·Filed Sep 04, 2026, 08:14 ET

SHARE PURCHASE AGREEMENT

This SHARE PURCHASE AGREEMENT (this “Agreement”) is dated as of August 31, 2026 (the “Effective Date”) by and between Charging Robotics Ltd., a company incorporated under the laws of the State of Israel (the “Company”), and the undersigned investor in the Investment (as defined below) (the “Investor”).

WITNESSETH:

WHEREAS, the Company is raising capital by way of an equity investment of US$2,500,000 ($16,778 per share) (the “Purchase Price” and “Investment”), by issuance of 149 ordinary shares of the Company, no par value per share (the “Ordinary Shares”), representing immediately after the Closing 51% of the Company’s issued and outstanding share capital on a fully diluted basis;

WHEREAS, the Investor’s purchase of Ordinary Shares will be made in accordance with and subject to the terms and conditions of this Agreement;

…

EX-10.1·8-K·CIK 1459188·ACC 0001213900-26-097409·Filed Sep 04, 2026, 07:35 ET

LOAN AGREEMENT

This Loan Agreement (this “Agreement”) is made and entered into as of August 31, 2026 (the “Effective Date”) between Charging Robotics Ltd. (the “Borrower”), and Clearmind Medicine Inc. (the “Lender”). Each of the Lender and the Borrower shall be referred to as “Party” and together as the “Parties”. Capitalized terms used but not defined in this Agreement shall have the meanings ascribed to them in the Share Purchase Agreement (as defined below).

…

EX-10.2·8-K·CIK 1459188·ACC 0001213900-26-097409·Filed Sep 04, 2026, 07:35 ET

BOARD APPOINTMENT AGREEMENT

This BOARD APPOINTMENT AGREEMENT (this “Agreement”), dated as of September 3, 2026, by and among USA Rare Earth, Inc., a Delaware corporation (the “Parent”) and VB (Rare Earths) Limited, a limited company incorporated under the Laws of Guernsey (the “Investor”).

1. Board Appointment Rights.

(a) Following the Closing and subject to the terms and conditions contained herein, as long as the 5% Beneficial Ownership Requirement is met the Investor shall have the right to (i) designate one (1) Investor Designee for appointment or election to the Board of Directors of Parent (the “Board”) and (ii) remove a duly elected or appointed Investor Director as a member of the Board (but only to the extent the Parent has the right to cause such removal). For the avoidance of doubt, from and after such time as the Investor first ceases to satisfy the 5% Beneficial Ownership Requirement, the designation and removal rights under immediately foregoing clauses (i) and (ii), respectively,

…

EX-10.2·8-K·CIK 1970622·ACC 0001213900-26-097399·Filed Sep 04, 2026, 07:11 ET

EXHIBIT 10.22

Black Hawk Acquisition Corp

THIS CONVERTIBLE NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

CONVERTIBLE NOTE

Principal Amount: Up to $300,000 Dated as of Aug 21, 2026

…

EX-10.22·S-4/A·CIK 1993074·ACC 0001829126-26-009732·Filed Sep 04, 2026, 06:03 ET

EX-10.2

Senti Biosciences Holdings, Inc.

EQUITY COMMITMENT LETTER

CPIF II-9 Limited

PO Box 500, Suite 210, 2nd Floor, Windward III, Regatta Office Park

Grand Cayman, Cayman Islands, KY1-1106

September 3, 2026

To: Senti Biosciences Holdings, Inc.

2 Corporate Drive, First Floor

South San Francisco, CA 94080

Ladies and Gentlemen:

This letter agreement sets forth the commitment of CPIF II-9 Limited (“Investor”) to Senti Biosciences Holdings, Inc. (“Company”) in connection with the Agreement and Plan of Merger dated July 14, 2026 (the “Merger Agreement”) among the Company, Investor, Senti Merger Sub, Inc. (“Merger Sub”), Senti Holdings, Inc. (“Midco”) and Senti Biosciences, Inc. (“Opco”). Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Merger Agreement.

…

EX-10.2·8-K·CIK 1854270·ACC 0001628280-26-060600·Filed Sep 04, 2026, 06:01 ET

EX-10.1

Senti Biosciences Holdings, Inc.

SENIOR SECURED CONVERTIBLE NOTE

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXCHANGEABLE OR CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED BY THE HOLDER, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY (IF REQUESTED BY THE COMPANY), THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT, OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE, INCLUDING SECTIONS 19(a) AND 19(e) HEREOF. THE PRINCIPAL AMOUNT REPRESENTED BY T

…

EX-10.1·8-K·CIK 1854270·ACC 0001628280-26-060600·Filed Sep 04, 2026, 06:01 ET